Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
23.66
-0.54 (-2.23%)
Aug 8, 2025, 3:36 PM - Market open
CTI BioPharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $25.7, which forecasts a 8.62% increase in the stock price over the next year. The lowest target is $23 and the highest is $28.
Price Target: $25.7 (+8.62%)
Analyst Consensus: Buy
* Price targets were last updated on Mar 7, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $24 → $24 | Hold | Maintains | $24 → $24 | -0.68% | Mar 7, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +9.89% | Dec 13, 2024 |
| Wolfe Research | Wolfe Research | Buy Initiates $28 | Buy | Initiates | $28 | +18.34% | Dec 13, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $24 → $23 | Hold | Initiates | $24 → $23 | -2.79% | Dec 3, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +18.34% | Aug 7, 2024 |
Financial Forecast
Revenue This Year
1.20B
from 1.10B
Increased by 8.60%
Revenue Next Year
1.32B
from 1.20B
Increased by 10.34%
EPS This Year
0.54
from 0.43
Increased by 25.51%
EPS Next Year
0.66
from 0.54
Increased by 22.40%
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 1.4B | 1.5B | ||
| Avg | 1.2B | 1.3B | 1.5B | ||
| Low | 1.1B | 1.3B | 1.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.8% | 15.3% | 16.8% | ||
| Avg | 8.6% | 10.3% | 10.5% | ||
| Low | 3.3% | 4.7% | 4.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.57 | 0.71 | 0.86 | ||
| Avg | 0.54 | 0.66 | 0.81 | ||
| Low | 0.51 | 0.62 | 0.74 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 31.9% | 32.3% | 30.7% | ||
| Avg | 25.5% | 22.4% | 23.0% | ||
| Low | 18.5% | 14.4% | 12.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.